חזרה לתוצאות החיפוש

A Phase 1 Study of AJ1-11095 in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), or Post-Essential Thrombocythemia Myelofibrosis (PET-MF) Who Have Been Failed by a Type I JAK2 Inhibitor (JAK2i)

חו"ל (דורש נסיעה)מגייס משתתפיםPHASE1

מצבים רפואיים

Primary Myelofibrosis · Post-Essential Thrombocythemia Myelofibrosis · Post-Polycythemia Vera Myelofibrosis · PMF · PPV-MF · PET-MF

סיכום בשפה פשוטהבעזרת בינה מלאכותית

הסיכום נכתב על־ידי מודל שפה והוא ניסיוני. המידע עלול להיות חלקי או שגוי ואינו תחליף לייעוץ רפואי.

מיקומים

  • Stanford Cancer Institute, Palo Alto, California, United States

    Contact: Study coordinator (William Shomali, MD) · 650-498-6000

  • Moffitt Cancer Cancer Center, Tampa, Florida, United States

    Contact: Study coordinator (Andrew Kuykendall, MD) · 813-745-4639

  • University of Kansas Medical Center, Kansas City, Kansas, United States

    Contact: Study coordinator (Abdulraheem Yacoub, MD)

  • Massachusetts General Hospital, Boston, Massachusetts, United States

    Contact: Study coordinator (Gabriela Hobbs, MD) · 617-724-1124

  • Dana Farber Cancer Institute, Boston, Massachusetts, United States

    Contact: Study coordinator (Jacqueline Garcia, MD) · 617-632-1906

  • University of Michigan, Ann Arbor, Michigan, United States

    Contact: Study coordinator (Kristen Pettit, MD) · 734-647-2829

  • Washington University School of Medicine, St Louis, Missouri, United States

    Contact: Study coordinator (Stephen Oh, MD) · 314-362-8814

  • David H. Koch Center for Cancer Care at Memorial Sloan Kettering, New York, New York, United States

    Contact: Study coordinator (Raajit Rampal, MD)

  • Icahn School of Medicine at Mount Sinai, New York, New York, United States

    Contact: Study coordinator (John Mascarenhas, MD) · 212-241-8839

  • Levine Cancer Institute, Charlotte, North Carolina, United States

    Contact: Study coordinator (Michael Grunwald, MD) · 980-442-4363

  • University of Cincinnati, Cincinnati, Ohio, United States

    Contact: Study coordinator (Eric Vick, MD) · 513-213-3203

  • The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

    Contact: Study coordinator (Uma Borate, MD) · 614-685-9828

  • MD Anderson Cancer Center, Houston, Texas, United States

    Contact: Study coordinator (Prithviraj Bose, MD) · 713-792-7747

  • AP-HP Hopital Saint-Louis, Paris, France

    Contact: Study coordinator (Jean-Jacques Kiladjian)

  • IRCCS Azienda Ospedaliero-Universitaria di Bologna - Policlinico di Sant Orsola, Bologna, Italy, Italy

    Contact: Study coordinator (Francesca Palandri, MD)

  • Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy, Italy

    Contact: Study coordinator (Francesco Passamonti, MD)

  • Hospital General Universitario Gregorio Maranon, Madrid, Spain, Spain

    Contact: Study coordinator (Santiago Osorio-Prendes, MD) · 0034915868443

  • Hospital Clinic Barcelona, Barcelona, Spain

    Contact: Study coordinator (Ana Moreno Triguero)

  • Hospital Universitario Ramon y Cajal, Madrid, Spain

    Contact: Study coordinator (Valentin Garcia-Gutierrez)

  • Guy's Hospital, London, UK, United Kingdom

    Contact: Study coordinator (Claire Harrison, MD) · 07939059512

  • Genesis Cancer Care UK Limited - Oxford, Oxford, UK, United Kingdom

    Contact: Study coordinator (Adam Mead, MD)
מובילי המחקר

  • John Mascarenhas, M.D.

    Principal Investigator

    Mt. Sinai

צפייה במקור ב־ClinicalTrials.gov(נפתח בחלון חדש)